About Target Discovery & Validation
The Target Discovery & Validation category is part of the AI Drug Discovery market map, tracking 13 companies building in this segment. Target discovery, molecular design, protein folding, and clinical trial optimization accelerating the path from lab to patient. Curated by Hartmann Capital's venture research team.
Companies in Target Discovery & Validation
- Recursion — Public, $452M
- Insitro — Series C, $700M
- Verge Genomics — Series B, $100M
- Cellarity — Series C, $294M
- Valo Health — Series B, $460M
- Xaira Therapeutics — Series A, $1B
- BenevolentAI — Public, $361M
- Enveda Biosciences — Series D, $400M
- Standigm — Pre-IPO, $71M
- Turbine AI — Series A, $38M
- Nimbus Therapeutics — Acquired, $637M
- Inductive Bio — Series A, $25M
- Spring Discovery — Series A, $16M
Frequently Asked Questions
- What companies are in the Target Discovery & Validation category?
- The Target Discovery & Validation category includes 13 companies: Recursion, Insitro, Verge Genomics, Cellarity, Valo Health, Xaira Therapeutics, BenevolentAI, Enveda Biosciences, Standigm, Turbine AI, Nimbus Therapeutics, Inductive Bio, Spring Discovery. This is part of the AI Drug Discovery market map maintained by Hartmann Capital.
- How many Target Discovery & Validation startups are tracked?
- Hartmann Capital tracks 13 companies in the Target Discovery & Validation segment of the AI Drug Discovery market map.
- What are the best funded Target Discovery & Validation companies?
- Top funded companies in Target Discovery & Validation include Xaira Therapeutics ($1000M), Insitro ($700M), Nimbus Therapeutics ($637M), Valo Health ($460M), Recursion ($452M). Browse the full list in the AI Drug Discovery market map.
- How can I submit my startup?
- You can submit your startup for inclusion by visiting the submission page. Submissions are reviewed by Hartmann Capital's research team.